StockData
Apimeds Pharmaceuticals US, Inc. logo

Apimeds Pharmaceuticals US, Inc. (APUS) stock

APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30
$1.95−0.09 (-4.41%)

Close on Nov 17, 2026Market cap $2.94MP/E –Yield –

Apimeds Pharmaceuticals US pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Apimeds Pharmaceuticals US

Apimeds Pharmaceuticals US has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Apimeds Pharmaceuticals US figures

See a number that looks wrong?